Foetal lung adenocarcinoma (FLAC) is a rare variant of lung adenocarcinoma. Studies regarding FLAC have been based only on histopathological observations, thus representative in vitro models of FLAC cultures are unavailable. We have established and characterized a human primary FLAC cell culture, exploring its biology, chemosensitivity and migration. FLAC cells and specimen showed significant upregulation of VEGF165 and HIF-1α mRNΑ levels. This observation was confirmed by in vitro chemosensitivity and migration assay, showing that only Axitinib was comparable to Cisplatin treatment. We provide a suitable in vitro model to further investigate the nature of this rare type of cancer.
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture / DE FALCO, Elena; Menna, Cecilia; Pacini, Luca; Scafetta, Gaia; Paola, Ruggieri; Puca, Rosa; Petrozza, Vincenzo; Ciccone, Annamaria; Rendina, Erino Angelo; Calogero, Antonella; Ibrahim, Mohsen. - In: CANCER INVESTIGATION. - ISSN 0735-7907. - ELETTRONICO. - 1:32(2014), pp. 13-21. [10.3109/07357907.2013.861472]
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture
DE FALCO, ELENA;Cecilia Menna;PACINI, LUCA;SCAFETTA, GAIA;PUCA, ROSA;PETROZZA, Vincenzo;Anna Maria Ciccone;RENDINA, Erino Angelo;CALOGERO, ANTONELLA;IBRAHIM, MOHSEN
2014
Abstract
Foetal lung adenocarcinoma (FLAC) is a rare variant of lung adenocarcinoma. Studies regarding FLAC have been based only on histopathological observations, thus representative in vitro models of FLAC cultures are unavailable. We have established and characterized a human primary FLAC cell culture, exploring its biology, chemosensitivity and migration. FLAC cells and specimen showed significant upregulation of VEGF165 and HIF-1α mRNΑ levels. This observation was confirmed by in vitro chemosensitivity and migration assay, showing that only Axitinib was comparable to Cisplatin treatment. We provide a suitable in vitro model to further investigate the nature of this rare type of cancer.File | Dimensione | Formato | |
---|---|---|---|
Menna_Axitinib_2014.pdf
solo gestori archivio
Note: article
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.